Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Common Equity (2020 - 2025)

GeneDx Holdings has reported Common Equity over the past 6 years, most recently at $308.2 million for Q4 2025.

  • Quarterly results put Common Equity at $308.2 million for Q4 2025, up 25.66% from a year ago — trailing twelve months through Dec 2025 was $308.2 million (up 25.66% YoY), and the annual figure for FY2025 was $308.2 million, up 25.66%.
  • Common Equity for Q4 2025 was $308.2 million at GeneDx Holdings, up from $292.3 million in the prior quarter.
  • Over the last five years, Common Equity for WGSWW hit a ceiling of $637.3 million in Q2 2022 and a floor of -$566.5 million in Q2 2021.
  • Median Common Equity over the past 5 years was $267.3 million (2025), compared with a mean of $228.3 million.
  • Peak annual rise in Common Equity hit 291.33% in 2021, while the deepest fall reached 283.41% in 2021.
  • GeneDx Holdings' Common Equity stood at $388.1 million in 2021, then plummeted by 34.63% to $253.7 million in 2022, then decreased by 10.13% to $228.0 million in 2023, then grew by 7.56% to $245.2 million in 2024, then increased by 25.66% to $308.2 million in 2025.
  • The last three reported values for Common Equity were $308.2 million (Q4 2025), $292.3 million (Q3 2025), and $277.1 million (Q2 2025) per Business Quant data.